Cancer may be tied to bacteria!

Gum disease is the result of advantageous bacteria that propagate when there is poor oral hygiene.

These bacteria create a general state of chronic inflammation, particularly in unhealthy individuals. I encourage you to look at a brilliant publication by Scientific American titled “Oral and Whole Body Health.” Among other things, are you aware that periodontal bacteria cause back pain and results in loss of height as we age?

Now we are beginning to see the first signs that bacteria and resulting inflammation has a potential association with cancer.

- Dr. Tom Lewis

Really?: Gum Disease Tied to Pancreatic Cancer Risk



Pancreatic cancera leading cause of cancer deaths, is elusive, with vague symptoms that often lead to late diagnosis. Because it is so lethal and hard to detect until its advanced stages, scientists have been looking for ways to spot it early. Now some researchers, including a team at Brown University, think gum disease may one day help identify people at greater risk.

Gum disease, which affects nearly half of all Americans, has been linked to stroke, diabetes and other ailments. The American Heart Association has disputed the notion that the association is causal, but some researchers speculate that poor gum health may give rise to chronic inflammation that promotes the growth of cancer cells.

In a recent study published in the journal Gut, the Brown researchers compared 405 people with pancreatic cancer and 416 who did not have the disease. The scientists found that higher levels of antibodies to P. gingivalis, a bacterium that plays a role in gum disease, were twice as common in people with pancreatic cancer.

To be sure, the research showed only an association, not a causal relationship. But other studies have also found intriguing results. One at Harvard found that men with poor gum health had a 63 percent higher risk of developing pancreatic cancer than men who did not have gum disease. And a New York University study found that high levels of P. gingivalis were linked to greater risk of dying of pancreatic and colorectal cancer, even in people without overt gum disease.


A few studies have suggested a possible link between gum disease and pancreatic cancer, though more research is needed.

Dr. Julian Kenyon

Colleen Huber

Dr. Julian Kenyon - Dove Clinic

Dr. Julian Kenyon – Dove Clinic

Note: In this book, 15 cancer doctors share the details of their treatment protocols and answer difficult questions about cancer.

Each physician is given their own chapter in the book.

The page you are viewing contains sample material.

Dr. Julian Kenyon (Doctor’s Website) is a physician of integrative medicine and Medical Director of The Dove Clinic for Integrated Medicine, which has locations in Winchester and London, England.

He is Founder-Chairman of the British Medical Acupuncture Society, which was established in 1980, and Co-Founder of the Centre for the Study of Complementary Medicine in Southampton and London, where he worked for many years before starting The Dove Clinic in 2000. He is also Founder-President of the British Society for Integrated Medicine and is an established authority in the field of complementary treatment approaches for a wide range of medical conditions.

He graduated from the University of Liverpool with a Bachelor of Medicine and Surgery degree in 1970, and subsequently with a Doctor of Medicine research degree. In 1972, he was appointed a Primary Fellow of the Royal College of Surgeons, Edinburgh. Dr. Kenyon has written approximately twenty books, has had many academic papers published in peer review journals and has been granted several patents. He has a particular interest in immune function and its relationship to the development of life-threatening illnesses and chronic disease in general.

The doctors and nurses who form The Dove Clinic team are committed to a multi-disciplinary and holistic approach to health care, which means giving equal attention to the body, mind, and spirit, in a caring, peaceful, and nurturing environment.

Dr. Kenyon’s wife, Tanya, works with him at The Dove Clinic. She has many years of experience as a trained nurse, counselor and complementary therapist.

What Cancer Is and What Causes It

Cancer is a wound that doesn’t heal. In normal wound healing, a lot of growth processes happen, but these processes stop when the wound is healed. In cancer, the growth processes don’t stop, and what results is a tumor that continues to grow unchecked. Environmental factors have possibly played a role in the increased incidence of cancer over the last fifty years, but it depends upon where people live. For example, in China there’s a lot of pollution and consequently, an increased incidence of a range of cancers, especially lung cancer.

To some extent, dietary changes are also related to the rapid increase in the occurrences of cancer.  In England, the longest-lived population was the mid-Victorian working class (the Victorian period was from 1837-1901). This has been well-studied, and research has established that these people lived longer than we do today.  Their cancer incidence was about ten percent of ours, and their cancers were mostly hereditary. The working class Victorians were mostly laborers, and the vats in which they stored their food were high in many different types of polyphenols, which are nutritional constituents of food that have anti-cancer properties.  These vats also contained significant amounts of oligosaccharides, which protected the people’s guts and in turn, aided in their cell-mediated immune function, which is the body’s main defense against cancer.  Also, they had large amounts of phytonutrients in their diets, which came from food that they grew themselves.

It’s hard to know specifically what factors are causing an increase in the incidence of cancer today. On an immunological level, cancer happens when the body switches from a Th-1 dominant, cell-mediated immune function response, to one in which it produces more antibodies, which is a Th-2 response. When the body produces too much of a Th-2 response, it makes people more susceptible to allergies such as hay fever, and causes their cell-mediated immune function, which the body needs to fight cancer, to be poor.   In people with cancer, there has been a movement away from a Th-1 dominated phenotype response to a Th-2 dominated phenotype response. Exposure to mycobacterium early in life can upregulate the body’s cell-mediated immune response, so factors such as the environment in which children are raised can determine the strength of their cell-mediated immune

The following are additional sections contained in this chapter:

  • Treatments
  • Sonodynamic and Photodynamic Therapy
  • Treatment Procedure Using Sonodynamic Photodynamic Therapy (SPDT)
  • Beta-glucans
  • Intravenous Vitamin C
  • Pancreatic Enzymes
  • Dendritic Cell Therapy Vaccines
  • Ukrain and Metronomic Low-Dose Cytophosphamide
  • The Use of Bindweed Root for Stopping Angiogenesis
  • Detoxification
  • Treating Hormonal Imbalances
  • Dietary Recommendations
  • Testing Procedures and Dark Field Microscopy
  • Other Considerations in Treatment
  • Maintenance Treatment Program
  • Treatment Outcomes
  • Lifestyle Recommendations for Healing
  • Roadblocks to Healing
  • Inexpensive Cancer Treatments
  • How Family and Friends Can Support Their Loved Ones with Cancer
  • Final Words

Cancer Related Medical Costs

State-level cancer care costs to jump as much as 115 percent by 2020

Cancer Treatment - State Level Cancer Care
“Over the past 20 years, the cost of treating cancer has nearly doubled nationally,” wrote authors Justin G. Trogdon, PhD, of RTI International in Research Triangle Park, N.C., and colleagues.

An analysis of cancer-related medical costs by state has projected that all U.S. states will see a substantial increase in the costs of care for cancer patients through 2020, according to the results of a study published in the September issue of The American Journal of Managed Care.

“As a result of an aging population and more expensive cancer treatments, the national costs of cancer care are expected to increase significantly in the near future,” they added, noting that the rate of increase will vary by state.

Projections were based on pooled Medical Expenditure Panel Survey data for 2004 to 2008, and U.S. Census Bureau population projections that were used for estimates of the number of people treated for cancer by age group and sex. The authors explained that their base model assumed no change in cancer treatment rates and a 3.6 percent annual increase in inflation-adjusted per capita medical costs.

Using the base model, between 2010 and 2020 projected state-level cancer-related medical costs would increase between 34 percent, in the District of Columbia, and 115 percent, in Arizona. The median increase is projected at 72 percent. In 2010 dollars, this translates into increases between $347 million and $28.3 billion, with a median increase of $3.7 billion in state-level costs.

“Our projections of state-level percentage increases in the number of treated cancer cases between 2010 and 2020 varied significantly across states and closely paralleled projected increases in the number of residents 65 years or older,” wrote the authors. “States with the largest projected percentage increases in number of residents 65 years or older also had the largest projected percentage increases in cancer-related medical costs.”

Trogdon and colleagues noted that the largest projected increases in the number of people treated for cancer were found in Florida (353,000), California (351,000) and Texas (249,000). Percentage change in the number of cancer cases treated during the projected period ranged from -7 percent in the District of Columbia to 46 percent in Arizona.

In looking for the main drivers of the rising costs, the authors explained that declining trends in U.S. cancer incidence rates and improving cancer survival rates have little net effect on overall cost projections.

However, costs of medical services was another story. Compared with the base model assumption of a 3.6 percent annual increase in medical costs, the authors explained that assumptions of 0 percent cost growth and 5 percent cost growth were 34 percent lower and 18 percent higher, respectively. Using the 0 percent cost-growth model is interesting, according to Trogdon and colleagues, because it better demonstrates the impact of population growth and aging, and at the same time might be more accurate since inflation-adjusted per-person cost of cancer treatment did not change much between 1987 and 2005.

“We hope that states find these projections useful as they try to make evidence-based decisions about the allocation of resources for cancer research and interventions as well as other policy decisions related to cancer prevention and treatment,” wrote the authors.